| Interleukin-6 receptor antagonists in critically ill patients with Covid-19–preliminary report Remap-Cap Investigators, AC Gordon, PR Mouncey, F Al-Beidh, ... MedRxiv, 2021.01. 07.21249390, 2021 | 1449 | 2021 |
| Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19 ATTACC, ACTIV-4a, and REMAP-CAP Investigators New England Journal of Medicine 385 (9), 790-802, 2021 | 1123 | 2021 |
| Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial DC Angus, L Derde, F Al-Beidh, D Annane, Y Arabi, A Beane, ... Jama 324 (13), 1317-1329, 2020 | 865 | 2020 |
| Interleukin-6 receptor antagonists in critically ill patients with Covid-19 Remap-Cap Investigators New England Journal of Medicine 384 (16), 1491-1502, 2021 | 656 | 2021 |
| Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury X Peng, PM Hassoun, S Sammani, BJ McVerry, MJ Burne, H Rabb, ... American journal of respiratory and critical care medicine 169 (11), 1245-1251, 2004 | 605 | 2004 |
| Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial MA Matthay, CS Calfee, H Zhuo, BT Thompson, JG Wilson, JE Levitt, ... The Lancet Respiratory Medicine 7 (2), 154-162, 2019 | 577 | 2019 |
| Pre–B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury SQ Ye, BA Simon, JP Maloney, A Zambelli-Weiner, L Gao, A Grant, ... American journal of respiratory and critical care medicine 171 (4), 361-370, 2005 | 520 | 2005 |
| Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis P Domingo, I Mur, GM Mateo, M del Mar Gutierrez, V Pomar, N de Benito, ... Jama 326 (6), 499-518, 2021 | 514 | 2021 |
| Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials C Axfors, AM Schmitt, P Janiaud, J Van’t Hooft, S Abd-Elsalam, EF Abdo, ... Nature communications 12 (1), 2349, 2021 | 368 | 2021 |
| In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights BJ McVerry, JGN Garcia Cellular signalling 17 (2), 131-139, 2005 | 268 | 2005 |
| Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury BJ McVerry, X Peng, PM Hassoun, S Sammani, BA Simon, JGN Garcia American journal of respiratory and critical care medicine 170 (9), 987-993, 2004 | 263 | 2004 |
| Endothelial cell barrier regulation by sphingosine 1‐phosphate BJ McVerry, JGN Garcia Journal of cellular biochemistry 92 (6), 1075-1085, 2004 | 235 | 2004 |
| Aging mesenchymal stem cells fail to protect because of impaired migration and antiinflammatory response ML Bustos, L Huleihel, MG Kapetanaki, CL Lino-Cardenas, L Mroz, ... American journal of respiratory and critical care medicine 189 (7), 787-798, 2014 | 210 | 2014 |
| Effect of convalescent plasma on organ support–free days in critically ill patients with COVID-19: a randomized clinical trial H Abdelhady, M Abdelrazik, Z Abdi, D Abdo, A Abdulle, L Abel, ... Jama 326 (17), 1690-1702, 2021 | 201 | 2021 |
| Dynamic regulation of cardiolipin by the lipid pump Atp8b1 determines the severity of lung injury in experimental pneumonia NB Ray, L Durairaj, BB Chen, BJ McVerry, AJ Ryan, M Donahoe, ... Nature medicine 16 (10), 1120-1127, 2010 | 150 | 2010 |
| A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulate inflammation BB Chen, TA Coon, JR Glasser, BJ McVerry, J Zhao, Y Zhao, C Zou, ... Nature immunology 14 (5), 470-479, 2013 | 137 | 2013 |
| COVID-19 versus non–COVID-19 acute respiratory distress syndrome: comparison of demographics, physiologic parameters, inflammatory biomarkers, and clinical outcomes W Bain, H Yang, FA Shah, T Suber, C Drohan, N Al-Yousif, RS DeSensi, ... Annals of the American Thoracic Society 18 (7), 1202-1210, 2021 | 136 | 2021 |
| Severe acute respiratory syndrome coronavirus 2 viremia is associated with coronavirus disease 2019 severity and predicts clinical outcomes JL Jacobs, W Bain, A Naqvi, B Staines, PMS Castanha, H Yang, VF Boltz, ... Clinical Infectious Diseases 74 (9), 1525-1533, 2022 | 127* | 2022 |
| Effect of P2Y12 inhibitors on survival free of organ support among non–critically ill hospitalized patients with COVID-19: a randomized clinical trial JS Berger, LZ Kornblith, MN Gong, HR Reynolds, M Cushman, Y Cheng, ... Jama 327 (3), 227-236, 2022 | 115 | 2022 |
| Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, A Kidwai, ... Jama 329 (1), 39-51, 2023 | 113 | 2023 |
John EvankovichUniversity of Pittsburgh School of MedicineDirección de correo verificada de upmc.edu